Stockscreener 앱 받기
7.26
4.60%
-0.35
시간 외 거래:
7.21
-0.05
-0.69%
Verrica Pharmaceuticals Inc 주식(VRCA)의 최신 뉴스
Verrica Pharmaceuticals (NASDAQ:VRCA) Upgraded to “Buy” at Wall Street Zen - Defense World
Market Fear: Is Verrica Pharmaceuticals Inc stock a value trapAnalyst Downgrade & Daily Chart Pattern Signals - baoquankhu1.vn
Trade Report: Is Verrica Pharmaceuticals Inc stock good for income investorsPortfolio Gains Summary & AI Based Trade Execution Alerts - baoquankhu1.vn
Verrica doses first patient in phase 3 wart trial, eyes major label expansion - MSN
Volume Recap: What is Life Time Group Holdings Incs P E ratio telling usJuly 2025 Gainers & Free Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
How Much Upside is Left in Verrica Pharmaceuticals (VRCA)? Wall Street Analysts Think 97.11% - sharewise.com
Verrica Pharmaceuticals Reports Q4 2024 Growth and Pipeline Progress - MSN
Verrica Pharmaceuticals Appoints Dr. Noah Rosenberg as Chief Medical Officer - MSN
Will Verrica Pharmaceuticals Inc. stock see insider buyingTrade Analysis Report & High Win Rate Trade Alerts - Улправда
Verrica Doses First Patient in Phase 3 Wart Trial, Eyes Major Label Expansion - MyChesCo
Why Verrica Pharmaceuticals Inc. stock is favored by top institutionsJuly 2025 Snapshot & Free Safe Entry Trade Signal Reports - ulpravda.ru
Will Verrica Pharmaceuticals Inc. stock benefit from green energy trendsRisk Management & Free Daily Entry Point Trade Alerts - ulpravda.ru
Will Verrica Pharmaceuticals Inc. (1NE) stock outperform benchmarks2025 Major Catalysts & Accurate Trade Setup Notifications - Улправда
Verrica doses first patient in phase 3 trial for common wart treatment - Investing.com Nigeria
First Patient Dosed in Phase 3 VP-102 Common Warts Program - Dermatology Times
Verrica Pharmaceuticals stock advances as TD Cowen reiterates Buy rating By Investing.com - Investing.com Nigeria
Verrica Pharmaceuticals stock advances as TD Cowen reiterates Buy rating - Investing.com India
Verrica Pharmaceuticals announces first patient dosed in phase 3 program - MarketScreener
Verrica Pharmaceuticals (VRCA) Begins Phase 3 Trials for Common Warts Treatment - GuruFocus
Verrica doses first patient in phase 3 trial for common wart treatment By Investing.com - Investing.com South Africa
Verrica Pharmaceuticals Announces First Patient Dosed in Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts - Chartmill
Verrica reports high response rate in skin cancer study - MSN
Verrica Pharmaceuticals adds Caligan Partner to board - MSN
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Short Interest Update - Defense World
Verrica Pharmaceuticals Adds Caligan Partner to Board - The Globe and Mail
Short Interest in Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Decreases By 26.2% - MarketBeat
Verrica Pharmaceuticals appoints Charles Frantzreb to board and approves equity grants - Investing.com Canada
Verrica Pharmaceuticals appoints Charles Frantzreb to board and approves equity grants By Investing.com - Investing.com South Africa
Verrica Pharmaceuticals Appoints New Director - TradingView — Track All Markets
Verrica Pharmaceuticals Inc. Appoints Charles Frantzreb as Director, Effective December 26, 2025 - marketscreener.com
Can Verrica Pharmaceuticals Inc. stock reach $100 price targetHigh Yield Income Stocks & Low Cost Portfolio Tips - bollywoodhelpline.com
Verrica Pharmaceuticals (VRCA) Stock Price, Quote, News & History - Benzinga
Verrica Pharmaceuticals upgraded to buy from hold at Brookline - MSN
Gains Report: Can Verrica Pharmaceuticals Inc. stock reach $100 price targetJuly 2025 Reactions & Entry Point Confirmation Signals - Улправда
Is Verrica Pharmaceuticals Inc. stock a safe buy before earningsTrade Analysis Report & AI Optimized Trading Strategy Guides - Улправда
Will Verrica Pharmaceuticals Inc. stock pay special dividendsQuarterly Performance Summary & AI Powered Market Entry Strategies - Улправда
With Verrica Pharmaceuticals Stock Surging, Have You Considered The Downside? - Trefis
Can Verrica Pharmaceuticals Inc. stock surprise with earnings upsideJuly 2025 Outlook & Verified Swing Trading Watchlists - Улправда
Verrica Pharmaceuticals (FRA:1NE0) EV-to-OCF : -4.47 (As of Dec. 19, 2025) - GuruFocus
Can Verrica Pharmaceuticals Inc. stock weather global recessionJuly 2025 Chart Watch & Smart Investment Allocation Tips - Улправда
Is Verrica Pharmaceuticals Inc. stock supported by innovation pipelineJuly 2025 Trade Ideas & High Accuracy Investment Entry Signals - Улправда
Is Verrica Pharmaceuticals Inc. stock a buy on dipsJuly 2025 Highlights & AI Powered Trade Plan Recommendations - Улправда
Will Verrica Pharmaceuticals Inc. (1NE) stock boost dividends furtherMarket Sentiment Review & Reliable Entry Point Alerts - DonanımHaber
Verrica Pharmaceuticals (NASDAQ:VRCA) Rating Increased to Buy at Brookline Capital Management - Defense World
Brookline Capital upgrades Verrica Pharmaceuticals (VRCA) - MSN
Aug Drivers: Will Verrica Pharmaceuticals Inc. stock see insider buyingMarket Sentiment Review & Weekly Top Gainers Alerts - Улправда
Is Verrica Pharmaceuticals Inc. (1NE) stock undervalued after correction2025 Sector Review & Verified Momentum Stock Alerts - Улправда
Verrica Pharmaceuticals (NASDAQ:VRCA) Stock Rating Upgraded by Brookline Capital Management - MarketBeat
Verrica Pharmaceuticals (VRCA) Receives Upgrade from Brookline C - GuruFocus
4.73%
0.92%
자본화:
|
볼륨(24시간):